Filtering by:
Non-small Cell Lung CancerLung Cancer Survivor Makes Wish For Peace
Back when lung cancer survivor Wendy Ryals still had a house and a job, she dreamed of someday saving enough money to help the homeless. But then she became homeless herself.
Researchers Report Advances in Lung Cancer Immunotherapy
Scientists presenting at the American Association for Cancer Research Annual Meeting in Chicago have found new and promising ways to use immunotherapy to treat people with some types of non-small cell lung cancer (NSCLC).
FDA Approves Imfinzi (Durvalumab) for Some Lung Cancers
The US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for people with stage III (3) non-small cell lung cancer who are not able to be treated with surgery to remove their tumor, and whose cancer has not gotten worse after they received chemotherapy along with radiation (chemoradiation).
FDA Approves a Biosimilar to Avastin for Cancer Treatment
The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) as the first biosimilar drug for treating cancer. It works the same way as Avastin (bevacizumab).
FDA Approves New Targeted Therapy Drug Combination for Lung Cancer
The US Food and Drug Administration (FDA) has approved the targeted therapy drugs Tafinlar (dabrafenib) and Mekinist (trametinib) to be used together to treat people with a specific type of non-small cell lung cancer that has spread in the body (metastasized).
Lung Cancer Survivor Faces Life’s Challenges Head-on
In 1998, Ruthe Cain was living life in California and enjoying being close to the fresh air and the great outdoors, but that year she would face a diagnosis that would change her life: she learned she had lung cancer.
Lung Cancer Survivor Copes With Unexpected Diagnosis
When her doctor told Julie Genovesi she had lung cancer, she was in complete denial. She argued with him, and told him to re-check the scans.
FDA OKs Xalkori (Crizotinib) for Rare Type of Advanced Lung Cancer
The US Food and Drug Administration (FDA) has approved the first treatment for people with advanced, ROS1-positive non-small cell lung cancer.
